Globus Medical Inc. (GMED) has emerged as a standout performer in the medical device sector, delivering consecutive quarters of earnings beats. The company's spine products, robotics solutions, and Nevro integration have positioned it as an attractive investment.
Robotics exceeded expectations by over $15 million, while spine outpaced projections by more than $40 million. The Nevro product line contributed an additional $9 million beat.
EBITDA margin reached 32.8% in Q3 2025, surpassing estimates of 30% and consensus of 27%. An additional 170 bps improvement is projected by early 2026.
At approximately 11 times next twelve months EBITDA, the stock appears reasonably priced. Analysts have raised price targets from $106 to $118 over recent months.
Risks include competitive pressures, Nevro integration, U.S. market concentration, and pricing challenges. However, strong robotics performance and expanding margins provide upside.
Barclays Capital on January 8, 2026: price target $118, Overweight rating.
